There are 3161 resources available
1265P - A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumours
Presenter: xianghai Cai
Session: Poster session 05
1266P - Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort
Presenter: Amanda Tufman
Session: Poster session 05
1267P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
Presenter: Naoto Takase
Session: Poster session 05
1268P - Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLC
Presenter: Jieun Park
Session: Poster session 05
1269P - Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II study
Presenter: Luis Paz-Ares
Session: Poster session 05
1270P - Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
Presenter: Sehhoon Park
Session: Poster session 05
1271P - Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC
Presenter: Hakan Bozcuk
Session: Poster session 05
1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 05
Resources:
Abstract
1274P - Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 05